Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model

被引:60
|
作者
Liang, Leilei [1 ]
Yu, Jing [1 ]
Li, Jian [1 ]
Li, Ning [1 ]
Liu, Jing [1 ]
Xiu, Lin [1 ]
Zeng, Jia [1 ]
Wang, Tiantian [1 ]
Wu, Lingying [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Gynecol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
国家重点研发计划;
关键词
ovarian cancer; scRNA-seq; myeloid cells; 2-gene signature; risk; prognosis; EXPRESSION; PROGNOSIS; GENOMICS;
D O I
10.3389/fonc.2021.711020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Considerable evidence suggests that the heterogeneity of ovarian cancer (OC) is a major cause of treatment failure. Single-cell RNA sequencing (scRNA-seq) is a powerful tool to analyse the heterogeneity of the tumour at the single-cell level, leading to a better understanding of cell function at the genetic and cellular levels. Methods OC scRNA-seq data were extracted from the Gene Expression Omnibus (GEO) database and the FindCluster () package used for cell cluster analysis. The GSVA package was used for single-sample gene set enrichment analysis (ssGSEA) analysis to obtain a Hallmark gene set score and bulk RNA-seq data were used to analyse the key genes of OC-associated immune cell subsets. CIBERSORT was used to identify immune scores of cells and the "WGCNA" package for the weighted correlation network analysis (WGCNA). KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) analyses of subtype groups were performed by GSEA. Then, univariate Cox and lasso regression were performed to further establish a signature. Finally, qPCR and immunohistochemistry staining were used to evaluate the expression of signature genes in OC. Results Two scRNA-seq (GSE154600 and GES158937) datasets were integrated to obtain 20 cell clusters. T cells or NK cells (cluster 5, 6, 7, 11), B cells (cluster 16, 19, 20) and myeloid cells (cluster 4, 9, 10) were clustered according to immune cell markers. The ssGSEA revealed that M1- and M2-like myeloid cell-related genes were significantly upregulated in P3 and P4 patients in the GSE154600 data. Immune cell analysis in TCGA-OC showed that a high abundance of M1-like tumour-associated macrophages (TAMS) predicts better survival. WGCNA, univariate Cox and lasso Cox regression established a two-gene signature (RiskScore=-0.059*CXCL13-0.034*IL26). Next, the TCGA-test and TCGA-OC were used to test the risk prediction ability of the signature, showing a good effect in the datasets. Moreover, the qPCR and immunohistochemistry staining revealed that the expression of CXCL13 and IL26 was reduced in OC tissues. Conclusion A two-gene signature prognostic stratification system (CXCL13 and IL26) was developed based on the heterogeneity of OC immune cells to accurately evaluate the prognostic risk.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Analysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-seq
    Liu, Xiaorui
    Li, Jingjing
    Wang, Qingxiang
    Bai, Lu
    Xing, Jiyuan
    Hu, Xiaobo
    Li, Shuang
    Li, Qinggang
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [2] Integration of scRNA-Seq and TCGA RNA-Seq to Analyze the Heterogeneity of HPV plus and HPV- Cervical Cancer Immune Cells and Establish Molecular Risk Models
    Wei, Erdong
    Reisinger, Amin
    Li, Jiahua
    French, Lars E.
    Clanner-Engelshofen, Benjamin
    Reinholz, Markus
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Integration of scRNA-Seq and Bulk RNA-Seq Reveals Molecular Characterization of the Immune Microenvironment in Acute Pancreatitis
    Fang, Zhen
    Li, Jie
    Cao, Feng
    Li, Fei
    [J]. BIOMOLECULES, 2023, 13 (01)
  • [4] ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma
    Yao, Wenchao
    Liu, Xuxu
    He, Yuanhang
    Tian, Maolan
    Lu, Shixin
    Wang, Qiang
    Zheng, Yi
    Lv, Zhenyi
    Hao, Chenjun
    Xue, Dongbo
    Meng, Xianzhi
    [J]. MOLECULAR THERAPY-ONCOLYTICS, 2022, 27 : 48 - 60
  • [5] Unveiling mitophagy-mediated molecular heterogeneity and development of a risk signature model for colorectal cancer by integrated scRNA-seq and bulk RNA-seq analysis
    Gao, Han
    Zou, Qi
    Ma, Linyun
    Cai, Keyu
    Sun, Yi
    Lu, Li
    Ren, Donglin
    Hu, Bang
    [J]. GASTROENTEROLOGY REPORT, 2023, 11
  • [6] Integration of scRNA-Seq and bulk RNA-Seq uncover perturbed immune cell types and pathways of Kawasaki disease
    Cao, Naixin
    Ouyang, Huayi
    Zhang, Xing
    Xu, Yuanyuan
    Li, Jun
    Chen, Yanfei
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq
    Xu, Jieyun
    Qin, Shijie
    Yi, Yunmeng
    Gao, Hanyu
    Liu, Xiaoqi
    Ma, Fei
    Guan, Miao
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [8] Integrating scRNA-seq and bulk RNA-seq to characterize infiltrating cells in the colorectal cancer tumor microenvironment and construct molecular risk models
    Wang, Qi
    Zhang, Yi-Fan
    Li, Chen-Long
    Wang, Yang
    Wu, Li
    Wang, Xing-Ru
    Huang, Tai
    Liu, Ge-Liang
    Chen, Xing
    Yu, Qi
    He, Pei-Feng
    [J]. AGING-US, 2023, 15 (23): : 13799 - 13821
  • [9] Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq
    Dongni Zhang
    Wenping Lu
    Shasha Cui
    Heting Mei
    Xiaoqing Wu
    Zhili Zhuo
    [J]. Journal of Ovarian Research, 15
  • [10] Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq
    Zhang, Dongni
    Lu, Wenping
    Cui, Shasha
    Mei, Heting
    Wu, Xiaoqing
    Zhuo, Zhili
    [J]. JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)